CL2008001996A1 - Composicion farmaceutica que comprende n-{4-(2,2-dimetil-propionil)-(5r)-5-[(2-etilamino-etanosulfonilamino)-metil]-5-fenil-4,5-dihidro-[1,3,4]tiadiazol-2-il}-2,2-dimetil-propionamida, un tampón y/o sal tartrato, fosfato, citrato, mesilato, fosfato de sodio o sulfato de sodio, en solución acuosa con ph menor que 5,4 y mayor que 2,0. - Google Patents

Composicion farmaceutica que comprende n-{4-(2,2-dimetil-propionil)-(5r)-5-[(2-etilamino-etanosulfonilamino)-metil]-5-fenil-4,5-dihidro-[1,3,4]tiadiazol-2-il}-2,2-dimetil-propionamida, un tampón y/o sal tartrato, fosfato, citrato, mesilato, fosfato de sodio o sulfato de sodio, en solución acuosa con ph menor que 5,4 y mayor que 2,0.

Info

Publication number
CL2008001996A1
CL2008001996A1 CL2008001996A CL2008001996A CL2008001996A1 CL 2008001996 A1 CL2008001996 A1 CL 2008001996A1 CL 2008001996 A CL2008001996 A CL 2008001996A CL 2008001996 A CL2008001996 A CL 2008001996A CL 2008001996 A1 CL2008001996 A1 CL 2008001996A1
Authority
CL
Chile
Prior art keywords
dimethyl
phosphate
pharmaceutical composition
ethanesulfonylamino
thiadiazol
Prior art date
Application number
CL2008001996A
Other languages
English (en)
Inventor
Kusano Hiroko
Shyamdeo Mishra Dinesh
Tashiro Yoshikazu
Watanabe Yosuke
Zhuang Hong
Original Assignee
Lilly Co Eli
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39735000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008001996(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Kyowa Hakko Kogyo Kk filed Critical Lilly Co Eli
Publication of CL2008001996A1 publication Critical patent/CL2008001996A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición farmacéutica y composición farmacéutica liofilizada que comprenden n-(4-(2,2-dimetil-propionil)-(5r)-5-((2-etilamino-etansulfonilamino)-metil)-5-fenil-4,5-dihidro-(1,3,4)tiadiazol-2-il)-2,2-imetil-propionamida, y un portador, diluyente o excipiente farmacéuticamente aceptable en solución, útil para tratar un tumor maligno.
CL2008001996A 2007-07-12 2008-07-07 Composicion farmaceutica que comprende n-{4-(2,2-dimetil-propionil)-(5r)-5-[(2-etilamino-etanosulfonilamino)-metil]-5-fenil-4,5-dihidro-[1,3,4]tiadiazol-2-il}-2,2-dimetil-propionamida, un tampón y/o sal tartrato, fosfato, citrato, mesilato, fosfato de sodio o sulfato de sodio, en solución acuosa con ph menor que 5,4 y mayor que 2,0. CL2008001996A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94926807P 2007-07-12 2007-07-12

Publications (1)

Publication Number Publication Date
CL2008001996A1 true CL2008001996A1 (es) 2009-05-22

Family

ID=39735000

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001996A CL2008001996A1 (es) 2007-07-12 2008-07-07 Composicion farmaceutica que comprende n-{4-(2,2-dimetil-propionil)-(5r)-5-[(2-etilamino-etanosulfonilamino)-metil]-5-fenil-4,5-dihidro-[1,3,4]tiadiazol-2-il}-2,2-dimetil-propionamida, un tampón y/o sal tartrato, fosfato, citrato, mesilato, fosfato de sodio o sulfato de sodio, en solución acuosa con ph menor que 5,4 y mayor que 2,0.

Country Status (28)

Country Link
US (1) US8222284B2 (es)
EP (1) EP2178508B1 (es)
JP (1) JP4875205B2 (es)
KR (1) KR101188036B1 (es)
CN (1) CN101730525A (es)
AR (1) AR067472A1 (es)
AU (1) AU2008275258A1 (es)
BR (1) BRPI0814039A2 (es)
CA (1) CA2694277C (es)
CL (1) CL2008001996A1 (es)
CO (1) CO6270304A2 (es)
CR (1) CR11210A (es)
DO (1) DOP2010000004A (es)
EA (1) EA016861B1 (es)
EC (1) ECSP109864A (es)
ES (1) ES2401477T3 (es)
GT (1) GT201000003A (es)
HK (1) HK1141238A1 (es)
IL (1) IL202382A0 (es)
MA (1) MA31880B1 (es)
MX (1) MX2010000468A (es)
NZ (1) NZ581791A (es)
PE (1) PE20090438A1 (es)
SV (1) SV2010003449A (es)
TN (1) TN2010000015A1 (es)
TW (1) TW200918050A (es)
UA (1) UA97672C2 (es)
WO (1) WO2009009470A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2447536B1 (en) 2009-06-26 2017-12-27 Mitsubishi Electric Corporation Refrigerant compressor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847534B9 (en) 2001-12-11 2012-03-21 Kyowa Hakko Kirin Co., Ltd. Thiadiazoline derivatives for treating cancer
EP1616866B1 (en) * 2003-04-18 2011-12-14 Kyowa Hakko Kirin Co., Ltd. M-stage kinesin inhibitor
JP2008150291A (ja) * 2005-03-22 2008-07-03 Kyowa Hakko Kogyo Co Ltd 乾癬治療剤
JPWO2006101103A1 (ja) * 2005-03-22 2008-09-04 協和醗酵工業株式会社 造血器腫瘍治療剤
KR20070113300A (ko) 2005-03-22 2007-11-28 교와 핫꼬 고교 가부시끼가이샤 고형종양 치료제
JP2008137893A (ja) * 2005-03-22 2008-06-19 Kyowa Hakko Kogyo Co Ltd 関節炎治療剤
JP2006265107A (ja) * 2005-03-22 2006-10-05 Kyowa Hakko Kogyo Co Ltd 緑内障治療剤
WO2006137490A1 (ja) * 2005-06-24 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. 再狭窄治療剤

Also Published As

Publication number Publication date
US20110009458A1 (en) 2011-01-13
MX2010000468A (es) 2010-04-09
EP2178508A1 (en) 2010-04-28
TW200918050A (en) 2009-05-01
IL202382A0 (en) 2010-06-30
PE20090438A1 (es) 2009-04-18
CO6270304A2 (es) 2011-04-20
CN101730525A (zh) 2010-06-09
AU2008275258A1 (en) 2009-01-15
ES2401477T3 (es) 2013-04-19
KR101188036B1 (ko) 2012-10-05
EP2178508B1 (en) 2013-02-06
TN2010000015A1 (en) 2011-09-26
HK1141238A1 (en) 2010-11-05
DOP2010000004A (es) 2010-03-15
UA97672C2 (ru) 2012-03-12
EA016861B1 (ru) 2012-08-30
CA2694277C (en) 2013-04-09
AR067472A1 (es) 2009-10-14
NZ581791A (en) 2012-03-30
US8222284B2 (en) 2012-07-17
KR20100029827A (ko) 2010-03-17
CA2694277A1 (en) 2009-01-15
CR11210A (es) 2010-06-23
MA31880B1 (fr) 2010-12-01
JP4875205B2 (ja) 2012-02-15
BRPI0814039A2 (pt) 2017-10-03
EA201070136A1 (ru) 2010-06-30
WO2009009470A1 (en) 2009-01-15
GT201000003A (es) 2012-03-13
JP2010533190A (ja) 2010-10-21
ECSP109864A (es) 2010-03-31
SV2010003449A (es) 2010-08-10

Similar Documents

Publication Publication Date Title
NO2008019I1 (no) N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-L,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-LH-pyrrol-3-karboksamid (sunitinib),samt farmasoeytisk akseptable salter
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
BRPI0518794A2 (pt) composto, composiÇço, mÉtodo de tratamento de distérbio hiperproliferativo, e, biblioteca combinatorial
RU2014134909A (ru) Азагетероциклические соединения
MY162174A (en) Azetidines mek inhibitors for the treatment of proliferative diseases
RU2009113615A (ru) Ингибитор киназы
MX2008002104A (es) Derivados de 1-acildihidropirazol.
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
CY1112281T1 (el) Αναστολεις διπεπτιδυλ πεπτιδασης για τη θεραπεια του διαβητη
PE20060240A1 (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
ATE294800T1 (de) N-(5-(((5-alkyl-2-oxazolyl)methyl)thio)-2- thiazolyl)-carboxamide als inhibitoren cyclinabhängiger kinasen
TW200607505A (en) Fused heterocyclic kinase inhibitors
CL2007001749A1 (es) Compuesto derivado de 2-arilamino-4-(heterociclo)aminopirimidina, inhibidores de la proteina quinasa c-alfa; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes, cancer, enfermedad cardiaca coronaria, aterosclerosis, entre otras.
ATE532789T1 (de) Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
MX2007002269A (es) Uso novedoso de compuestos peptidos para tratar dolor por c??ncer de huesos, dolor inducido por quimioterapia y nucleosidos.
ATE500831T1 (de) Krebsbehandlungsverfahren
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
JP2010526862A (ja) がんの処置のための相乗的な医薬の組合せ
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
EA201001859A1 (ru) Гетероциклические производные мочевины и способы их применеия
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
IL198465A0 (en) Triazabenzo[e]azulene derivatives for the treatment of tumors